J Kros

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. ncbi Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH)
    J M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Pathol 188:282-8. 1999
  2. ncbi Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neurosurg 97:1390-6. 2002
  3. ncbi Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics
    Johan M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Acta Neuropathol 104:144-8. 2002
  4. ncbi [Meningiomas: prognostic relevance of histopathologic and genetic markers]
    J M Kros
    afd Pathologie, Erasmus Universitair Medisch Centrum, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 145:2160-5. 2001
  5. ncbi Spatial variability of genomic aberrations in a large glioblastoma resection specimen
    J M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, The Netherlands
    Acta Neuropathol 102:103-9. 2001
  6. ncbi NF2 status of meningiomas is associated with tumour localization and histology
    J Kros
    Department of Pathology of the Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    J Pathol 194:367-72. 2001
  7. ncbi Papillary meningioma with pleural metastasis: case report and literature review
    J M Kros
    Department of Pathology, University Hospital Rotterdam, The Netherlands
    Acta Neurol Scand 102:200-2. 2000
  8. ncbi Immunophenotype of pleomorphic xanthoastrocytoma
    Caterina Giannini
    Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 26:479-85. 2002
  9. ncbi Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Elize M Biemond ter Stege
    Department of Neurology Neuro Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 103:802-9. 2005
  10. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005

Collaborators

Detail Information

Publications44

  1. ncbi Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH)
    J M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Pathol 188:282-8. 1999
    ..The frequent losses of 14q have not been reported previously. In the two cases of mixed oligoastrocytomas multiple gains and losses were found that did not show a clear overlap with the alterations found in the pure oligodendrogliomas...
  2. ncbi Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neurosurg 97:1390-6. 2002
    ..In the present study, the contribution of both FR3 single and FR2 seminested PCR procedures for confirming the diagnosis of PCNSL was estimated retrospectively in 30 cases of PCNSL and in three cases of epidural lymphoma...
  3. ncbi Desmoplastic infantile astrocytoma and ganglioglioma: a search for genomic characteristics
    Johan M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Acta Neuropathol 104:144-8. 2002
    ..DNA-aneuploidy seems not to be indicative of tumor progression. It is concluded that the genetic aberrations found in desmoplastic infantile ganglioglioma differ from those encountered in common astrocytomas...
  4. ncbi [Meningiomas: prognostic relevance of histopathologic and genetic markers]
    J M Kros
    afd Pathologie, Erasmus Universitair Medisch Centrum, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 145:2160-5. 2001
    ..Molecular studies of relevant genetic defects involved in meningioma are currently underway, but as yet these are of little clinical relevance...
  5. ncbi Spatial variability of genomic aberrations in a large glioblastoma resection specimen
    J M Kros
    Department of Pathology, University Hospital Rotterdam Dijkzigt, The Netherlands
    Acta Neuropathol 102:103-9. 2001
    ..The findings illustrate the importance of searching for high-grade genetic aberrations in low-grade tumor samples taken from cases in which sampling error is suspected...
  6. ncbi NF2 status of meningiomas is associated with tumour localization and histology
    J Kros
    Department of Pathology of the Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    J Pathol 194:367-72. 2001
    ..006). Based on these findings, it is concluded that an alternative histogenesis and genetic pathway is likely to exist for meningiomas arising in the anterior skull base...
  7. ncbi Papillary meningioma with pleural metastasis: case report and literature review
    J M Kros
    Department of Pathology, University Hospital Rotterdam, The Netherlands
    Acta Neurol Scand 102:200-2. 2000
    ..Only 8 cases gave rise to metastases outside the central nervous system. The preferential site of metastasis appeared to be the lung. This is the first report of a papillary meningioma giving rise to a metastasis in the pleura...
  8. ncbi Immunophenotype of pleomorphic xanthoastrocytoma
    Caterina Giannini
    Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 26:479-85. 2002
    ..We found no evidence that the former is a precursor of the latter...
  9. ncbi Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Elize M Biemond ter Stege
    Department of Neurology Neuro Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 103:802-9. 2005
    ..The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD...
  10. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  11. ncbi Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:545-51. 2007
    ..The absence of necrosis and the presence of endothelial abnormalities were correlated with better outcomes. In multivariate analysis, patients' age, 1p/19q loss, and necrosis were identified as independent prognostic factors...
  12. ncbi Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis
    Judith M de Bont
    Department of Pediatric Oncology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:505-16. 2007
    ..Ongoing studies are focused on characterizing the role of these proteins as tumor markers and potential drug targets in pediatric brain tumors...
  13. ncbi Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies
    Jan Werner Poley
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Cancer 109:2349-56. 2007
    ..Therefore, the authors studied the role of homozygosity or compound heterozygosity (CZ) for MMR gene defects in children with multiple primary tumors...
  14. ncbi Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels
    Dana A N Mustafa
    Department of Pathology, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GD Rotterdam, The Netherlands
    Mol Cell Proteomics 6:1147-57. 2007
    ..This work proves that gel-free mass spectrometric techniques can be used on relatively small numbers of cells generated by microdissection procedures to successfully identify differentially expressed proteins...
  15. ncbi 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
    Mathilde C M Kouwenhoven
    Department of Neuro Oncology, Daniel den Hoed Oncology Center, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:2499-503. 2006
    ..We assessed the impact of 1p and 19q loss on the outcome to first line temozolomide (TMZ) chemotherapy and to second line PCV or TMZ in progressive oligodendroglial tumours...
  16. ncbi Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling
    Judith M de Bont
    Erasmus MC Sophia Children s Hospital University Medical Center Rotterdam, Department of Pediatric Oncology and Hematology, Rotterdam, The Netherlands
    Clin Chem 52:1501-9. 2006
    ..Our aim was to detect differences in protein expression profiles of cerebrospinal fluid (CSF) from pediatric patients with and without brain tumors...
  17. ncbi Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays
    Pim J French
    Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 67:5635-42. 2007
    ..The splice variants identified by exon level expression profiling may help to detect the genetic changes that cause or maintain gliomas and may serve as novel treatment targets...
  18. ncbi Predictive and prognostic markers in neuro-oncology
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:1074-81. 2007
    ..Last but not least there is the question of what added value the test has; this criterion determines the clinical usefulness of the assay and why some recently introduced molecular assays need to be scrutinized...
  19. pmc Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  20. pmc Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis
    Judith M de Bont
    Department of Pediatric Oncology and Hematology, Erasmus MC Sophia Children s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Neuro Oncol 10:648-60. 2008
    ....
  21. doi Desmoplastic infantile ganglioglioma with a malignant course
    Eelco W Hoving
    Departments of Neurosurgery, University Medical Center Groningen, Groningen, The Netherlands
    J Neurosurg Pediatr 1:95-8. 2008
    ..The progressive clinical course was determined by this cell component in spite of GTR and adjuvant chemotherapy. The significance of the presence of a high-grade primitive tumor component in the context of DIG is discussed...
  22. doi Chromosome 1p loss evaluation in anaplastic oligodendrogliomas
    Ahmed Idbaih
    INSERM, Unité 711, Paris, France
    Neuropathology 28:440-3. 2008
    ..Our results illustrate that aCGH (or other multiple loci technologies) provide complementary information to single locus technologies such as FISH because multiple loci technologies can evaluate the extent of the chr 1p deletion...
  23. ncbi Combining laser capture microdissection and proteomics techniques
    Dana Mustafa
    Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands
    Methods Mol Biol 428:159-78. 2008
    ..Obviously, validation of result is essential. The present review describes and discusses the various methods developed to target cell populations of interest by laser microdissection, followed by analysis of their proteome...
  24. doi Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
    Jerzy Hildebrand
    Hopital Universitaire Erasme, Brussels, Belgium
    Eur J Cancer 44:1210-6. 2008
    ..The aim of the present study was to test this adjuvant regimen in a larger number of AA patients...
  25. doi A 40-year-old woman with a progressive periventricular white matter lesion
    Jeroen de Jong
    Brain Pathol 18:103-4, 142. 2008
  26. ncbi Intratumoral distribution of 1p loss in oligodendroglial tumors
    Johan M Kros
    Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 66:1118-23. 2007
    ..918, p < 0.001). These results point to genotypic homogeneity for 1p in oligodendroglial tumors...
  27. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for leptomeningeal pilomyxoid astrocytoma: a case study
    Roelien H Enting
    J Neurooncol 80:107-8. 2006
  28. ncbi Gene expression profiles associated with treatment response in oligodendrogliomas
    Pim J French
    Department of Neurology, Cancer Genomics Center, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer Res 65:11335-44. 2005
    ..The differentially expressed transcripts can help identify patient subgroups with good prognosis and those that will benefit from chemotherapeutic treatments...
  29. ncbi Genetic aberrations in gliomatosis cerebri support monoclonal tumorigenesis
    Johan M Kros
    Department of Pathology, University Hospital Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 61:806-14. 2002
    ..The wide distribution of a particular set of genetic aberrations in this case supports the concept of monoclonal tumor proliferation. The results point to involvement of TP53 mutation in the tumorigenesis of gliomatosis cerebri...
  30. ncbi Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by Raman spectroscopy
    Senada Koljenovic
    Department of General Surgery 10M, Erasmus University Rotterdam and University Hospital Rotterdam Dijkzigt, Rotterdam, The Netherlands
    Lab Invest 82:1265-77. 2002
    ..This in vitro result indicates that Raman spectra contain the information to distinguish vital glioblastoma from necrosis and makes Raman spectroscopy a powerful candidate for guidance of stereotactic brain biopsy...
  31. ncbi Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity
    Johanna M M Gijtenbeek
    Department of Neurology, University Medical Center Nijmegen, The Netherlands
    J Neurosurg 97:977-82. 2002
    ..The aim of this study was to analyze further both sporadic HBs and VHL-related HBs to determine if these histopathologically identical tumors have a different genetic background...
  32. ncbi Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications
    Arie Perry
    Division of Neuropathology, Washington University School of Medicine, St Louis, Missouri 63110 1093, USA
    J Neuropathol Exp Neurol 61:947-55. 2002
    ..In any case, their occurrence suggests a histogenetic overlap between oligodendroglioma and extraventricular neurocytoma not previously recognized...
  33. ncbi Proteomics in primary brain tumors
    Ping Pin Zheng
    Department of Pathology, Erasmus Medical Center Rotterdam, The Netherlands
    Front Biosci 8:d451-63. 2003
    ..Various technical approaches to separate and identify proteins are described, including the most recent developments in the analytical proteomic technology...
  34. ncbi Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
    Martin J van den Bent
    Department of Neurooncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Cancer 97:1276-84. 2003
    ..The authors investigated the correlation between genetic and clinical characteristics of OD in 33 patients who received chemotherapy with procarbazine, lomustine, and vincristine for recurrent disease after receiving radiotherapy...
  35. ncbi Congenital bilateral plexiform neurofibromas of the cavernous sinuses
    Valerie A Meersschaut
    Department of Paediatric Radiology, University Hospital Rotterdam, Dr Molenwaterplein 60, 3015 GJ Rotterdam, The Netherlands
    Pediatr Radiol 33:272-4. 2003
    ..A dural tail sign was observed. The diagnosis was proven by biopsy...
  36. ncbi Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors
    Ping Pin Zheng
    Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Neuropathol Exp Neurol 62:855-62. 2003
    ..It is concluded that the combination of 2D PAGE and MALDI-TOF-MS is successful as an unbiased global screening tool for CSF...
  37. ncbi Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R
    Esther van Herpen
    Department of Clinical Genetics, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Ann Neurol 54:573-81. 2003
    ..All six tau isoforms were present in soluble brain tau. Recombinant tau proteins with the L315R mutation showed a reduced ability to promote microtubule assembly...
  38. pmc Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature
    Ping Pin Zheng
    Department of Pathology, Internal Oncology, Neuro Oncology and Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Pathol 164:2217-28. 2004
    ..The event coexists with tight junction (TJ) breakdown of the endothelial cells in glioma microvasculature. The data reveal a novel mechanism contributing to dysfunctionality of glioma neovascularization...
  39. ncbi Low-molecular weight caldesmon as a potential serum marker for glioma
    Ping Pin Zheng
    Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands
    Clin Cancer Res 11:4388-92. 2005
    ..Testing the feasibility of using the serum low-molecular weight caldesmon (l-CaD) level as a serum marker for the presence of glioma...
  40. ncbi Multiplex ligation-dependent probe amplification for the detection of 1p and 19q chromosomal loss in oligodendroglial tumors
    Remco Natté
    Department of Pathology, Leiden University Medical Center, P O Box 9600, 2300RC, Leiden, The Netherlands
    Brain Pathol 15:192-7. 2005
    ..We conclude that MLPA is a valid and reproducible method for the detection of 1p/19q chromosomal deletions in OGs stored on formalin fixed, paraffin embedded tissue...
  41. ncbi Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Biol Ther 4:1270-4. 2005
    ..The latter may imply that these wild-type c-KIT and PDGFR tumor types will probably not benefit from imatinib treatment...
  42. ncbi Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas
    Erkan Kurt
    Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 106:388-95. 2006
    ..Furthermore, in many investigations, myxopapillary ependymomas and subependymomas were included and may have confounded results, because those tumors should be considered clinicopathologic entities distinct from the other ependymomas...
  43. ncbi Lack of genetic and epigenetic changes in meningiomas without NF2 loss
    Angela A G van Tilborg
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    J Pathol 208:564-73. 2006
    ....
  44. ncbi Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas
    Takao Watanabe
    Unit of Molecular Pathology, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Acta Neuropathol 103:267-75. 2002
    ..There was no correlation with LOH on chromosomes 1p/19q, suggesting that MGMT may not be a prognostic marker for oligodendrogliomas...